BOLT Reports $2.5M Q4 Rev, $7.7M FY Rev, $31.8M Cash, $5.0M Q4 R&D, $28.5M FY R&D, BDC-4182 Phase 1 Data 3Q2026
Bolt Biotherapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $5.31
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS